dynlt5 Antibody

What is DYNLT5 and why is it significant for research investigations?

DYNLT5 (previously TCTEX1D1) is a dynein light chain protein predicted to enable dynein intermediate chain binding activity and participate in microtubule-based movement. It is a component of cytoplasmic dynein complexes with activity primarily in the cytoplasm . The significance of DYNLT5 derives from its association with primary ciliary dyskinesia types 22 and 38, and its involvement in organelle biogenesis, maintenance, and intraflagellar transport pathways . Unlike the more extensively studied DYNLL1, which functions in TLR4-mediated antibody responses and regulates the NF-κB pathway , DYNLT5's precise mechanisms remain less characterized, making antibodies against this protein valuable tools for expanding our understanding of dynein complex function in normal physiology and disease states.

What are the optimal fixation methods for immunohistochemical detection of DYNLT5?

For reliable immunohistochemical detection of DYNLT5, researchers should consider both cross-linking (formaldehyde-based) and precipitating (methanol/acetone) fixatives, as the optimal method depends on antibody epitope accessibility. A methodological approach involves:

• Testing both 4% paraformaldehyde (PFA) fixation (10-15 minutes at room temperature) and ice-cold methanol fixation (5 minutes at -20°C)

• Including antigen retrieval steps for PFA-fixed samples (typically citrate buffer pH 6.0 or Tris-EDTA pH 9.0)

• Determining optimal antibody concentration through titration experiments (typically 1-10 μg/ml range)

• Including appropriate controls with known DYNLT5 expression patterns

The choice between fixation methods should be guided by preservation of target epitopes while maintaining cellular architecture, particularly when examining DYNLT5's association with cytoplasmic dynein complexes.

What cross-reactivity considerations are important when selecting DYNLT5 antibodies?

When selecting DYNLT5 antibodies, researchers must carefully evaluate potential cross-reactivity with paralogous proteins, particularly DYNLT2B, which is an important paralog of DYNLT5 . Methodological approaches to address cross-reactivity include:

• Reviewing antibody validation data showing specificity tests against related dynein light chain family members

• Performing Western blot analysis to confirm single-band detection at the expected molecular weight (approximately 20 kDa for DYNLT5)

• Including knockout/knockdown validation controls when possible

• Testing antibodies on tissues/cells with differential expression of DYNLT5 and related proteins

• Considering epitope locations - antibodies targeting unique regions of DYNLT5 rather than conserved dynein domains will minimize cross-reactivity

This methodological evaluation is critical for ensuring accurate interpretation of experimental results, particularly in studies examining dynein complex composition and function.

How should researchers optimize Western blot protocols specifically for DYNLT5 detection?

Optimizing Western blot protocols for DYNLT5 requires careful consideration of protein extraction, separation, and detection parameters. A methodological approach includes:

Additionally, researchers should consider including dephosphorylation controls to determine if phosphorylation status affects antibody recognition, as dynein components are subject to post-translational modifications that can influence antibody binding.

What are the key considerations for co-immunoprecipitation experiments using DYNLT5 antibodies?

For successful co-immunoprecipitation (co-IP) of DYNLT5 and its binding partners, researchers should consider these methodological approaches:

• Lysis buffer optimization: Use mild non-denaturing lysis buffers (e.g., 1% NP-40 or 0.5% Triton X-100) to preserve protein-protein interactions within the dynein complex.

• Cross-linking considerations: For transient or weak interactions, consider reversible cross-linkers like DSP (dithiobis[succinimidyl propionate]) at 1-2 mM for 30 minutes prior to lysis.

• Antibody selection: Choose antibodies validated for immunoprecipitation applications with demonstrated ability to recognize native (non-denatured) DYNLT5.

• Pre-clearing strategy: Implement thorough pre-clearing (1 hour at 4°C with protein A/G beads) to reduce non-specific binding.

• Controls design:

  • Input control (5-10% of lysate)

  • IgG control (matched isotype)

  • IP without lysate

  • Reverse IP where possible (IP known interactors and probe for DYNLT5)

• Elution techniques: Compare different elution methods (SDS, low pH, peptide competition) to identify optimal recovery while minimizing antibody contamination.

• Detection strategy: For low-abundance interactions, consider mass spectrometry-based approaches rather than relying solely on Western blot detection.

This methodological framework helps ensure that genuine DYNLT5 interaction partners are identified while minimizing artifacts.

How can researchers confirm antibody specificity for DYNLT5 over other dynein light chain family members?

Verifying DYNLT5 antibody specificity requires multiple complementary approaches:

• Recombinant protein panel testing: Express and purify recombinant DYNLT5 alongside related proteins (particularly DYNLT2B and other DYNLT family members) and perform Western blot analysis to assess cross-reactivity.

• Gene silencing validation: Implement siRNA or shRNA-mediated knockdown of DYNLT5 and confirm signal reduction in immunoassays. Cross-validation with multiple DYNLT5-targeting sequences minimizes off-target effects.

• CRISPR/Cas9 knockout validation: Generate DYNLT5 knockout cell lines as gold-standard negative controls for antibody validation.

• Epitope mapping: Utilize peptide arrays or deletion mutants to precisely identify antibody binding regions and compare with sequence conservation among family members.

• Competitive binding assays: Pre-incubate antibodies with excess recombinant DYNLT5 or synthetic peptides corresponding to the epitope before application to samples.

• Tissue expression profiling: Compare antibody staining patterns with known DYNLT5 mRNA expression profiles across tissues to assess concordance.

This multi-dimensional validation approach ensures that observed signals genuinely represent DYNLT5 rather than related dynein light chain proteins.

How do DYNLT5 antibodies perform in proximity ligation assays for studying protein-protein interactions in situ?

Proximity Ligation Assay (PLA) offers powerful in situ detection of DYNLT5 interactions with spatial resolution. Methodological considerations include:

• Antibody compatibility: For successful PLA, primary antibodies must be raised in different species (e.g., rabbit anti-DYNLT5 and mouse anti-interactor), requiring careful antibody selection.

• Fixation optimization: Test both cross-linking (4% PFA) and alcohol-based fixatives to determine optimal preservation of interaction epitopes.

• Permeabilization parameters: Adjust permeabilization conditions (0.1-0.5% Triton X-100 or 0.05-0.2% Saponin) to balance antibody accessibility with preservation of cellular structures.

• Proximity threshold calibration: Consider that PLA signals appear when proteins are within 40nm, which may detect proteins within the same complex rather than direct interactions.

• Controls design:

  • Omission of primary antibodies

  • Single primary antibody controls

  • Known interaction partners as positive controls

  • Biological negative controls (interactions disrupted by specific treatments)

• Signal quantification: Employ automated image analysis with defined parameters for PLA puncta counting, intensity measurement, and cellular localization.

This methodological framework enables researchers to visualize DYNLT5 interactions within their native cellular context while minimizing artifacts and misinterpretation.

What considerations are important when using DYNLT5 antibodies for immunofluorescence in ciliated cells?

When investigating DYNLT5 localization in ciliated cells, researchers should implement these methodological approaches:

• Sample preparation: For primary cilia, serum starvation (24-48 hours) maximizes ciliation rates in appropriate cell types. For motile cilia, air-liquid interface culture may be necessary for respiratory cells.

• Fixation optimization: Test both methanol (preserves axonemal structures) and PFA (better membrane preservation) fixation methods to determine optimal DYNLT5 epitope accessibility.

• Cilia markers: Co-stain with established ciliary markers:

  • Acetylated tubulin or ARL13B for ciliary axoneme

  • γ-tubulin for basal bodies

  • IFT88 for intraflagellar transport components

• Super-resolution considerations: Given the small diameter of cilia (200-300nm), consider super-resolution microscopy techniques (STED, SIM, STORM) for precise localization within ciliary subdomains.

• Live imaging adaptations: For dynamic studies, consider fluorescently tagged DYNLT5 constructs validated against antibody staining patterns.

• Disease model comparisons: Include ciliopathy models (particularly primary ciliary dyskinesia types 22 and 38) to assess pathological DYNLT5 localization patterns.

This comprehensive approach enables accurate characterization of DYNLT5's ciliary localization and potential roles in ciliopathies.

How can researchers resolve contradictory DYNLT5 antibody staining patterns observed in different cell types?

When faced with discordant DYNLT5 antibody staining patterns across cell types, researchers should implement a systematic troubleshooting approach:

• Antibody epitope analysis: Different antibodies may recognize distinct DYNLT5 epitopes that could be differentially accessible depending on protein interactions or post-translational modifications. Test multiple antibodies targeting different regions.

• Isoform consideration: Verify if cell-specific splice variants or isoforms exist for DYNLT5 that might affect epitope presence or accessibility.

• Expression level normalization: Quantitative PCR and Western blot analysis of DYNLT5 expression levels across cell types can contextualize staining intensity differences.

• Subcellular fractionation: Perform biochemical fractionation to determine if DYNLT5 redistributes between soluble and insoluble compartments in different cell types.

• Interactome mapping: Immunoprecipitation followed by mass spectrometry in different cell types can identify cell-specific binding partners that might mask antibody epitopes.

• Functional perturbation: Employ siRNA knockdown in multiple cell types to confirm specificity of diminished signals.

• Cross-validation with tagged constructs: Express tagged DYNLT5 constructs and compare localization patterns with antibody staining.

This systematic approach helps distinguish genuine biological differences from technical artifacts in DYNLT5 localization studies.

How do experimental approaches for DYNLT5 antibodies compare with methods for other dynein light chain proteins like DYNLL1?

While both DYNLT5 and DYNLL1 are dynein light chain proteins, their distinct biological roles necessitate different experimental approaches:

Understanding these differences enables researchers to design experiments that appropriately target the unique biological contexts of each protein.

What methodological approaches can distinguish between primary ciliary dyskinesia types 22 and 38 using DYNLT5 antibodies?

For differential diagnosis of primary ciliary dyskinesia (PCD) types 22 and 38 using DYNLT5 antibodies, researchers should implement this methodological framework:

• Mutation-specific antibody selection: Design or select antibodies that can distinguish between wild-type DYNLT5 and common PCD-causing mutations.

• Tissue sampling approach: Obtain nasal or bronchial epithelial cells through minimally invasive brushing techniques for primary culture and analysis.

• Immunofluorescence protocol optimization:

  • Use high-resolution confocal or super-resolution microscopy

  • Co-stain with axonemal markers and other PCD-associated proteins

  • Quantify DYNLT5 staining intensity and distribution along the ciliary axoneme

• Functional correlation studies:

  • Correlate antibody staining patterns with ciliary beat frequency measurements

  • Assess DYNLT5 dynamics during ciliary beating using live cell approaches

  • Compare DYNLT5 localization between static and actively beating cilia

• Differential staining patterns:

  • PCD type 22: May show altered DYNLT5 distribution pattern while maintaining protein expression

  • PCD type 38: Might exhibit reduced or absent DYNLT5 staining depending on mutation type

• Antibody epitope considerations: Ensure antibodies can detect mutant forms of DYNLT5 typically found in PCD patients, or deliberately select antibodies that specifically distinguish wild-type from mutant forms.

This methodological approach helps establish reliable immunodiagnostic criteria for DYNLT5-related ciliopathies.

How can researchers effectively employ DYNLT5 antibodies in ChIP-seq experiments to investigate potential DNA binding activities?

While DYNLT5 is primarily known as a cytoplasmic protein, investigating potential nuclear functions requires specialized Chromatin Immunoprecipitation (ChIP) approaches:

• Nuclear localization verification: Before conducting ChIP-seq, confirm nuclear localization of DYNLT5 using subcellular fractionation and immunofluorescence with appropriate controls.

• Cross-linking optimization: Test both formaldehyde (1% for 10 minutes) and dual cross-linking approaches (1 mM DSG followed by 1% formaldehyde) to capture potentially indirect DNA associations.

• Sonication parameters: Optimize chromatin fragmentation to 200-500bp fragments, verifying size distribution by agarose gel electrophoresis.

• Antibody selection criteria:

  • Validate antibodies specifically for ChIP applications

  • Perform preliminary ChIP-qPCR on candidate regions before sequencing

  • Include isotype control antibodies and input samples as essential controls

• Bioinformatic analysis framework:

  • Employ both narrow and broad peak calling algorithms

  • Consider indirect binding through interaction with known DNA-binding proteins

  • Perform motif enrichment analysis to identify potential consensus sequences

  • Integrate with RNA-seq data to correlate binding with transcriptional effects

• Validation strategy: Confirm key findings with ChIP-qPCR, reporter assays, and mutational analyses.

This comprehensive approach enables exploration of potential non-canonical nuclear functions of DYNLT5, if they exist.

What are the key considerations for developing quantitative ELISA assays to measure DYNLT5 levels in biological samples?

Developing robust quantitative ELISA for DYNLT5 requires careful methodological planning:

• Antibody pair selection: For sandwich ELISA, identify capture and detection antibodies targeting non-overlapping epitopes of DYNLT5. Test multiple combinations to optimize signal-to-noise ratio.

• Standard curve generation: Express and purify recombinant DYNLT5 protein with verified identity by mass spectrometry. Prepare standards in the same matrix as samples to minimize matrix effects.

• Sample preparation protocol:

  • Determine optimal lysis conditions that maximize DYNLT5 extraction while maintaining epitope integrity

  • Assess need for detergents to solubilize membrane-associated DYNLT5

  • Evaluate potential interfering substances in biological matrices

• Assay optimization parameters:

• Validation criteria:

  • Sensitivity: Determine limit of detection and quantification

  • Specificity: Test against related proteins, particularly DYNLT2B

  • Precision: Assess intra- and inter-assay variability (CV <15% target)

  • Recovery: Spike-in experiments with known amounts of recombinant DYNLT5

  • Linearity: Serial dilution of samples should yield proportional results

• Clinical/biological validation: Compare ELISA results with Western blot quantification and correlate with disease states or experimental conditions.

This methodological framework enables development of reliable quantitative assays for DYNLT5 in research and potentially clinical applications.

How can single-cell protein analysis techniques be adapted for studying DYNLT5 in heterogeneous tissue samples?

Applying single-cell protein analysis techniques to DYNLT5 in heterogeneous tissues requires specialized methodological approaches:

• Tissue dissociation optimization: Develop gentle enzymatic dissociation protocols (using enzymes such as papain or liberase) that preserve DYNLT5 epitopes while achieving single-cell suspensions.

• Mass cytometry (CyTOF) adaptation:

  • Metal-conjugate DYNLT5 antibodies with rare earth metals

  • Include markers for cell type identification and ciliary status

  • Develop barcoding strategies for sample multiplexing

  • Implement dimensionality reduction techniques (t-SNE, UMAP) for visualization

• Single-cell Western blot considerations:

  • Optimize cell capture on microwell arrays

  • Determine lysis conditions that effectively solubilize DYNLT5

  • Develop detection strategies for low-abundance DYNLT5

• Imaging mass cytometry for spatial context:

  • Optimize staining protocols for tissue sections

  • Balance multiplexing capacity with resolution requirements

  • Develop computational approaches to identify spatial relationships between DYNLT5+ cells

• Correlation with single-cell transcriptomics:

  • Consider CITE-seq or REAP-seq approaches combining protein and RNA analysis

  • Develop computational methods to correlate DYNLT5 protein levels with transcript expression

  • Identify post-transcriptional regulatory mechanisms through protein-RNA discordance

• Validation strategy:

  • Confirm key findings with traditional immunohistochemistry

  • Employ cell sorting followed by bulk analysis for identified subpopulations

  • Perform functional assays on isolated cell populations

This methodological framework enables characterization of cell-specific DYNLT5 expression and function in complex tissues, particularly those with ciliated and non-ciliated cell populations.